간질성 방광염(IC) : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Interstitial Cystitis (IC) Emerging Therapy and TPP Insights

Thelansis's "Interstitial Cystitis (IC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Interstitial Cystitis (IC) Overview

Interstitial cystitis (IC), or bladder pain syndrome, is a chronic disorder causing recurrent pelvic pain, urgency, and frequency without infection, driven by urothelial dysfunction, hyperpermeability, and neurogenic sensitization. Pain characteristically worsens with bladder filling and is relieved by voiding. Diagnosis is clinical, requiring the exclusion of confusable conditions via cystoscopy and culture; a distinct Hunner lesion phenotype requires localized endoscopic identification. Rather than a rigid stepwise ladder, 2026 guidelines mandate a simultaneous, phenotype-directed multimodal strategy. Initial care combines trigger avoidance with pelvic floor physiotherapy. Oral amitriptyline provides systemic relief, while oral pentosan polysulfate is strictly restricted due to irreversible pigmentary maculopathy risks. Intravesical lidocaine or heparin instillations address mucosal symptoms, and Hunner lesions are treated with endoscopic fulguration. Refractory disease utilizes intradetrusor botulinum toxin or sacral neuromodulation.

Key Highlights

• In Germany, the prevalent population of Interstitial Cystitis (IC) is projected to increase from 831,982 in 2025 to 840,339 by 2035.
• Interstitial Cystitis is a chronic bladder disorder characterized by pelvic pain, urinary urgency, and increased urinary frequency, significantly impacting quality of life.
• The heterogeneous nature of the disease and lack of definitive diagnostic biomarkers continue to pose challenges for timely diagnosis and effective management.
• Despite the availability of multiple treatment approaches, substantial unmet need remains for therapies that provide durable symptom relief and address underlying disease mechanisms.

Market Overview

• The Italy Interstitial Cystitis market is projected to grow from $85M in 2025 to $155M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnosis among patients with chronic bladder pain symptoms
• Ongoing development of novel therapies targeting pain, inflammation, and bladder dysfunction
• Future growth will depend on the availability of more effective treatments capable of delivering sustained symptom control and improving patient quality of life.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Ono Pharmaceutical Co., Ltd.
• Imbrium Therapeutics
• Vaneltix Pharma, Inc.
• AbbVie

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)